Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

284
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
284
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

341
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
341
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

385
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
385
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

182
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
182
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

585
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
585
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary Flow Reserve in Adults: Pathophysiology, Assessment Modalities, Clinical Applications, and Prognostic Significance.

Medicina (Kaunas, Lithuania)·2026
Same author

Empiric Antifungal Therapy Is Not Associated with Improved Infectious Outcomes in Penetrating Upper Gastrointestinal Injuries: A Subgroup Analysis of the Surgical Infection Society Multi-Center Observational Study.

Surgical infections·2026
Same author

Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD.

Cancers·2026
Same author

ASO Visual Abstract: Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study.

Annals of surgical oncology·2026
Same author

Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study.

Annals of surgical oncology·2026
Same author

The Epidemiologic Comparison of Two Correlated Relative Risks: A Simple but Efficient Clinical Trial Design for Assessing Risk-Reduction and Treatment Significance.

Medicina (Kaunas, Lithuania)·2026
Same journal

The CALLY Index as a Predictive Tool for Surgical Site Infection After Pancreaticoduodenectomy: A Retrospective Cohort Study.

Surgical infections·2026
Same journal

Preoperative Prediction of Acute Appendicitis Pathological Type and Complicating Perforation Using IL-6 and IL-10.

Surgical infections·2026
Same journal

Outcomes and Predictors of Fungal Necrotizing Soft Tissue Infections.

Surgical infections·2026
Same journal

Light at the End of the Tunnel! Effects of 405 nm Visible Light Disinfection on Surgical Site Infection: A Prospective Randomized Cohort Study.

Surgical infections·2026
Same journal

Guideline-Directed Administration of Prophylactic Antibiotic-Loaded Bone Cement in Total Knee Arthroplasty Does Not Lower Infection Rate.

Surgical infections·2026
Same journal

Highlights from the 38th Annual Meeting of the Japanese Society of Surgical Infection.

Surgical infections·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Vancomycin-Associated Nephrotoxicity: The Obesity Factor.

Stephen W Davies1, Jimmy T Efird2, Christopher A Guidry1

  • 11 Department of General Surgery, University of Virginia School of Medicine , Charlottesville, Virginia.

Surgical Infections
|September 2, 2015
PubMed
Summary
This summary is machine-generated.

Obese patients treated with vancomycin did not experience a higher risk of nephrotoxicity compared to lean patients. This study found no significant difference in kidney damage between the two groups when using actual body weight dosing.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction
09:15

Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction

Published on: January 12, 2020

6.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction
09:15

Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction

Published on: January 12, 2020

6.9K

Area of Science:

  • Pharmacology
  • Nephrology
  • Infectious Diseases

Background:

  • Current vancomycin dosing guidelines recommend using actual body weight for obese patients.
  • This approach may increase the risk of nephrotoxicity in obese individuals.
  • This study investigated nephrotoxicity incidence in vancomycin-treated obese versus lean patients.

Purpose of the Study:

  • To compare the incidence of vancomycin-induced nephrotoxicity in obese and lean patients.
  • To evaluate the impact of actual body weight-based dosing on nephrotoxicity risk in obese patients.

Main Methods:

  • Retrospective cohort study of vancomycin-treated patients (2005-2009).
  • Patients stratified by body mass index (BMI): obese (≥30 kg/m²) vs. lean (<30 kg/m²).
  • Generalized estimating equations and multivariable analysis used to assess nephrotoxicity risk.

Main Results:

  • 530 patients (207 obese, 323 lean) with 1,007 infection episodes analyzed.
  • Obesity associated with female gender, diabetes mellitus, and hypertension.
  • No significant association found between obesity and increased nephrotoxicity risk (RR=0.98; 95% CI=0.93-1.04; p=0.59) after adjusting for covariates.

Conclusions:

  • Vancomycin dosing based on actual body weight did not result in a higher incidence of nephrotoxicity in obese patients.
  • No significant difference in nephrotoxicity was observed between lean and obese patients receiving vancomycin.